Senotherapeutics for mesenchymal stem cell senescence and rejuvenation
Document Type
Article
Publication Date
1-1-2023
Abstract
Mesenchymal stem cells (MSCs) are susceptible to replicative senescence and senescence-associated functional decline, which hampers their use in regenerative medicine. Senotherapeutics are drugs that target cellular senescence through senolytic and senomorphic functions to induce apoptosis and suppress chronic inflammation caused by the senescence-associated secreted phenotype (SASP), respectively. Therefore, senotherapeutics could delay aging-associated degeneration. They could also be used to eliminate senescent MSCs during in vitro expansion or bioprocessing for transplantation. In this review, we discuss the role of senotherapeutics in MSC senescence, rejuvenation, and transplan-tation, with examples of some tested compounds in vitro. The prospects, challenges, and the way forward in clinical applications of senotherapeutics in cell-based therapeutics are also discussed.
Keywords
Cellular senescence, Rejuvenation, Senolytics, Senomorphics, Stem cell therapy
Divisions
fac_med
Funders
Universiti Malaya Impact-Oriented Interdisciplinary Research Grant (Grant No: IIRG001- 2020FNW),Universiti Malaya SATU Joint Research Scheme (Grant No: ST031-2020)
Publication Title
Drug Discovery Today
Volume
28
Issue
1
Publisher
Elsevier Science Ltd
Publisher Location
THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND